Author Title Type [ Year(Desc)]
Filters: Author is Wu, Depei  [Clear All Filters]
Bazarbachi, A.Hamid, Hamed, R.Al, Labopin, M., Afanasyev, B., Hamladji, R.-M., Beelen, D., Eder, M., Scheid, C., Wu, D., Bunjes, D., et al. (2019). Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party.Bone Marrow Transplant.
Ke, P., Bao, X., Zhou, J., Zhu, Q., Zhuang, J., Hu, X., Liu, Y., Wu, D., Xue, S., Zhang, X., et al. (2019). Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation in Children.Acta Haematol1-7.
Li, C., Zhang, Y., Zhang, C., Chen, J., Lou, X., Chen, X., Kang, L., Xu, N., Li, M., Tan, J., et al. (2019). Comparation of CART19 and autologous stem-cell transplantation for refractory/relapsed non-Hodgkin's lymphoma.Jci Insight5.
Shouval, R., Labopin, M., Gorin, N.C., Bomze, D., Houhou, M., Blaise, D., Zuckerman, T., Baerlocher, G.M., Capria, S., Forcade, E., et al. (2019). Individualized prediction of leukemia-free survival after autologous stem cell transplantation in acute myeloid leukemia.Cancer.
Huang, H., Zhang, L., Jiang, Y., Liu, S., Jin, Z., Chen, J., Xiao, X., Ruan, J., Zhang, X., and Wu, D. (2019). Modified BuCy is an alternative conditioning regimen for lymphoma patients undergoing autologous stem cell transplantation.Ann Hematol.
Xuan, L., Wang, Y., Chen, J., Jiang, E., Gao, L., Wu, B., Deng, L., Liang, X., Huang, F., Fan, Z., et al. (2019). Sorafenib therapy is associated with improved outcomes for FLT3-ITD AML relapsing after allo-HSCT.Biol Blood Marrow Transplant.